Monitor Invivyd's BLA submission progress and FDA feedback over the next 12 months. The transition period mitigates immediate revenue loss, but failure to secure full approval could render the company without a marketed product. Stock price likely to reflect binary BLA outcome risk.
Drug in focus
IVVD drug pipeline →PEMGARDA
▼ Bearish Named in this 8-K- Impact
- Phase
- Authorized (EUA)
- Time to market
- Already on market under EUA since March 2024. EUA terminates June 29, 2027 unless converted to full BLA approval. BLA pathway being explored.
- Next catalyst
- None dated
What to watchThe EUA termination notice (effective June 2027) puts a clock on PEMGARDA's revenue stream and makes BLA conversion or VYD2311 success existential for Invivyd. Watch for VYD2311 Phase 3 LIBERTY/DECLARATION topline data expected Q3 2026, that will be the next major price catalyst, not a PEMGARDA event. The stock has substantial institutional support but faces significant regulatory overhang.
How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 6 $0.8340entry
- T+1 · 4mo ago +12.93%α +13.40% · $0.9418
- T+5 · 4mo ago −6.07%α −6.56% · $0.7834
- T+20 · 4mo ago −35.85%α −35.29% · $0.5350
- T+60 · 7w ago +1.93%α +0.02% · $0.8501
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Invivyd (IVVD) announced receipt of a 12-month advanced notice of EUA termination for its only authorized product, PEMGARDA (pemivibart), following HHS termination of the COVID-19 EUA declaration effective June 29, 2027. The company intends to pursue a BLA for full FDA approval and is in active dialogue with the FDA. The termination removes the product's current authorization but provides a transition period; the outcome of the BLA path is uncertain.
Key Facts
- FDA sent Notice of Termination for PEMGARDA EUA, effective June 29, 2027 (12-month transition period).
- HHS announced termination of the COVID-19 EUA declaration on June 30, 2026, effective June 29, 2027.
- Invivyd intends to submit a Biologics License Application (BLA) for full approval of PEMGARDA.
- PEMGARDA is Invivyd's only authorized product, used for pre-exposure prophylaxis of COVID-19 in immunocompromised individuals.
- Chairman Marc Elia stated belief that PEMGARDA has sufficient clinical and post-authorization data to support BLA approval.
Financial Impact
EUA termination removes current revenue stream from PEMGARDA; company's future revenue depends on BLA outcome. No financial figures provided in filing.
Risk Factors
- FDA may not approve BLA, leaving Invivyd without a marketed product after June 2027.
- Competing monoclonal antibodies or vaccines may reduce market need for PEMGARDA.
- Company may require additional capital to fund operations through BLA review.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-295539 |
| Document: ivvd-ex99_1.htm | 0001193125-26-295539 |
| Document: 0001193125-26-295539-index-headers.html | 0001193125-26-295539 |
| Document: 0001193125-26-295539-index.html | 0001193125-26-295539 |
| Document: 0001193125-26-295539.txt | 0001193125-26-295539 |
Track record
19 reports on IVVD
2 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +3.45% at T+1 after the Mar 5, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 16, 2026today Press Release Neutral 6/10 Entry $0.5603 Now $0.5380 −3.98% settles Nov 23
- Nov 3, 202613d ago Press Release Neutral 2/10 Entry $0.5815 to $0.5744 Now $0.5380 −7.48% ▼ −1.22% −0.63% vs SPY
- Sep 29, 20266w ago 8-K Bullish 7/10 Entry $0.8501 to $0.8064 Now $0.5380 −36.71% ▼ −5.14% −7.09% vs SPY
- Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $0.9640 to $0.8501 Now $0.5380 −44.19% ▼ −11.82% −10.63% vs SPY
- Sep 1, 202610w ago 8-K Neutral 6/10 Entry $0.8800 to $0.7973 Now $0.5380 −38.86% ▼ −9.40% −9.48% vs SPY
- Aug 17, 202613w ago 144 Neutral 2/10 Entry $0.8680 to $0.9387 Now $0.5380 −38.02% ▲ +8.15% +8.35% vs SPY
- Jul 6, 202619w ago 8-K Bearish 6/10 Viewing Entry $0.8340 to $0.7834 Now $0.5380 +35.49% ▲ +6.07% +6.56% vs SPY
- Jun 16, 202621w ago Press Release Neutral 5/10 Entry $0.8918 to $0.9346 Now $0.5380 −39.67% ▲ +4.80% +7.03% vs SPY
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $0.8125 to $0.9312 Now $0.5380 −33.78% ▲ +14.61% +14.18% vs SPY
- Jun 9, 202622w ago Press Release Neutral 4/10 Entry $0.9900 to $0.8686 Now $0.5380 −45.66% ▼ −12.26% −14.67% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers